- Home
- ADXN vs CURX Comparison
ADXN vs CURX Comparison
Compare ADXN & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | CURX |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 11.6M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ADXN | CURX |
|---|---|---|
| Price | $6.88 | $0.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.2K | ★ 5.9M |
| Earning Date | 01-01-0001 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.29 | $0.26 |
| 52 Week High | $12.05 | $9.18 |
Technical Indicators
Market Signals| Indicator | ADXN | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 54.69 |
| Support Level | $6.84 | $0.38 |
| Resistance Level | $8.74 | $0.42 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 34.10 | 30.46 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.